Lipid and Lipoprotein Disorders

Current Clinical Solutions - Lipid and Lipoprotein Disorders

Lipids Guidelines Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/76511

Contents of this Issue

Navigation

Page 9 of 27

Diagnosis and Assessment of Disease Table 2. Risk Categories 10-Year CHD Risk8-14, a High Risk Any one of the following: 1. History of CVD event (acute coronary syndrome, myocardial infarction [MI], coronary revascularization [percutaneous transluminal coronary angioplasty, stent, coronary artery bypass graft], cerebrovascular accident, carotid revascularization [stent, endarterectomy]) 2. CHD risk equivalent diagnosis (DM, chronic kidney disease, peripheral vascular disease, abdominal aortic aneurysm) 4. Coronary calcium score > 400 or presence of carotid plaquec 3. Two or more risk factors (RF) and > 20% estimated 10-year CHD risk Note: Combination of any 10-year High- Risk Criteria PLUS one of the following enhances risk: ▶ 2 or more RF ▶ 1 or more poorly controlled RF ▶ Metabolic syndrome plus CHD equivalent ▶ Elevated Lp(a). More aggressive targets may be considered based on clinical judgment Moderate Risk Any one of the following: 1. Family history of CHD in 1st degree relative < age 55 male or < age 65 female 2. Two or more RF with 5-20% 10-year CHD risk Note: Presence of 2 or more RF with 10-20% 10-year CHD risk may prompt selection of more aggressive targets based on clinical judgment. Low Risk 0-1 RF (not including family history early CHD) with < 5% 10-year CHD risk Ideal values for all of the following:b 1. TC < 180 2. HDL-C male > 40 or female > 50 3. Non-smoker 4. Untreated BP < 120 systolic and < 80 diastolic 5. Non-diabetic 6. BMI < 25.0d 7. No family history of CHD in 1st degree relative < age 55 male or < age 65 female. a 10-year CHD risk calculated using a validated risk assessment method (Framingham, Reynolds, MESA). b c Increased risk present in multiple prospective observational trials. 8 d Lifetime risk modeled in Framingham Heart Study using values at age 50 in disease free adults. Lifetime risk modeled in meta-analysis of 257,384 men and women whose cardiovascular risk factors were measured at the ages of 45, 55, 65, and 75 years. Any one of the following in a non-smoking, non- diabetic subject: 1. Family history of CHD in 1st degree male relative < age 55 or female < age 65 2. Untreated BP 120-139 systolic or 80-89 diastolic.b 3. BMI > 25.0d 4. HDL-C < 40 men or < 50 womenb Note: Presence of BMI > 30d BP 140-159 or diastolic BP 90-99, further enhances risk. , or untreated systolic More aggressive targets may be considered based on clinical judgment Lifetime CHD Risk9, 15-18, b Any one of the following: 1. History of CVD event (acute coronary syndrome, MI, coronary revascularization [percutaneous transluminal coronary angioplasty, stent, coronary artery bypass graft], cerebrovascular accident, carotid revascularization [stent, endarterectomy]) or familial 2. Any CHD risk equivalent diagnosis (DM, chronic kidney disease, peripheral vascular disease, abdominal aortic aneurysm) 3. Metabolic syndromec hypercholesterolemiac 4. Any of the following single risk factors:d ▶ TC > 240 mg/dL or treated hypercholesterolemia 5. Subclinical vascular disease (detected by invasive, or noninvasive [carotid plaque; coronary calcium score or CIMT > 75th percentile following adjustment for age, gender, ethnicity], imaging studies)c ▶ Treated hypertension (HTN) or untreated systolic > 160 or diastolic > 100 ▶ Active smoking Note: Combination of any Lifetime High-Risk Criteria PLUS one of the following further enhances risk: ▶ 2 or more RF ▶ Metabolic syndrome plus CHD equivalent ▶ Elevated Lp(a). More aggressive targets may be considered based on clinical judgment

Articles in this issue

Archives of this issue

view archives of Lipid and Lipoprotein Disorders - Current Clinical Solutions - Lipid and Lipoprotein Disorders